Clinical Trial Update: A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study of birabresib (MK-8628) in recurrent glioblastoma multiforme was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• MK-8628 (Birabresib)
• birabresib (birabresib)

Snippet

Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Glioblastoma Multiforme | Phase 2 | Status: TERMINATED | Results posted: 2018-05-17